{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T07:39:03Z","timestamp":1787989143399,"version":"build-2784847793"},"reference-count":42,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T00:00:00Z","timestamp":1774224000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are increasingly prescribed for type 2 diabetes in addition to other conditions such as obesity. As their use expands, understanding potential ocular safety signals is important, particularly in populations already at risk for diabetic eye disease. The aim of this study is to identify potential pharmacovigilance safety signals for ocular adverse events (AEs) related to GLP-1 RA medications to better inform future clinical practice. Methods: This study utilized the publicly available FDA Adverse Event Reporting System (FAERS) to obtain AE reports related to exenatide, tirzepatide, dulaglutide, liraglutide, and semaglutide from 2005 to 2024. Reports were categorized by demographic and geographic variables. Disproportionality analysis using reporting odds ratios (RORs) was performed to detect potential safety signals. Year-over-year trends in the proportional representation of each drug were also assessed through linear regression and time series plots. Results: Ocular AEs represented 3.61% of all GLP-1 RA related reports. Median age was 63 years, and 62.6% of reports involved female patients. Exenatide accounted for 33.61% of ocular AEs but showed a significant annual decline in reporting (\u20135.15% per year, p &lt; 0.001). Semaglutide (31.37%) and tirzepatide (12.19%) demonstrated significant year-over-year increases in proportional reporting (2.23% and 0.79% per year, respectively; both p &lt; 0.05), consistent with rapid uptake in clinical practice. Semaglutide demonstrated a modestly elevated ROR (1.46), while tirzepatide showed a low ROR (0.42), though this likely reflects shorter post-marketing exposure rather than lower clinical risk. The most frequently reported events were visual impairment, followed by vision blurred, cataract, and blindness. Conclusions: This pharmacovigilance analysis identifies potential ocular AE signals associated with GLP-1 RAs, particularly semaglutide. While semaglutide showed a statistically significant disproportional reporting signal for ocular AEs, the absence of exposure denominators, comparator groups, and the susceptibility of FAERS to reporting bias means these findings are hypothesis-generating rather than causal. Clinicians should remain vigilant and consider eye care referrals when indicated. Further research is needed to validate these associations and clarify underlying mechanisms.<\/jats:p>","DOI":"10.3390\/jcm15062464","type":"journal-article","created":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T15:54:53Z","timestamp":1774281293000},"page":"2464","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Pharmacovigilance Analysis of Ocular Adverse Events Associated with GLP-1 Receptor Agonists"],"prefix":"10.3390","volume":"15","author":[{"given":"Abdullah","family":"Virk","sequence":"first","affiliation":[{"name":"College of Medicine-Phoenix, University of Arizona, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3100-9545","authenticated-orcid":false,"given":"Karen","family":"Allison","sequence":"additional","affiliation":[{"name":"Flaum Eye Institute, University of Rochester, Rochester, NY 14642, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.2147\/DMSO.S319895","article-title":"A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives","volume":"14","author":"Reed","year":"2021","journal-title":"Diabetes Metab. Syndr. Obes. Targets Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.2337\/dc17-1962","article-title":"Global Economic Burden of Diabetes in Adults: Projections From 2015 to 2030","volume":"41","author":"Bommer","year":"2018","journal-title":"Diabetes Care"},{"key":"ref_3","unstructured":"CDC (2025, April 16). Type 2 Diabetes. Diabetes, Available online: https:\/\/www.cdc.gov\/diabetes\/about\/about-type-2-diabetes.html."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0140-6736(13)62154-6","article-title":"Pathophysiology and Treatment of Type 2 Diabetes: Perspectives on The Past, Present and Future","volume":"383","author":"Kahn","year":"2014","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"92","DOI":"10.4239\/wjd.v6.i1.92","article-title":"Ocular complications of diabetes mellitus","volume":"6","author":"Sayin","year":"2015","journal-title":"World J. Diabetes"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Alali, N.M., Albazei, A., Alotaibi, H.M., Almohammadi, A.M., Alsirhani, E.K., Alanazi, T.S., Alshammri, B.J., Alqahtani, M.Q., Magliyah, M., and Alreshidi, S. (2022). Diabetic Retinopathy and Eye Screening: Diabetic Patients Standpoint, Their Practice, and Barriers; A Cross-Sectional Study. J. Clin. Med., 11.","DOI":"10.3390\/jcm11216351"},{"key":"ref_7","unstructured":"Collins, L., and Costello, R.A. (2025, April 16). Glucagon-Like Peptide-1 Receptor Agonists, StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK551568\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, Physiology, and Mechanisms of Incretin Hormone Action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"212607","DOI":"10.7573\/dic.212607","article-title":"Management of type 2 diabetes: Consensus of diabetes organizations","volume":"9","author":"Quattrocchi","year":"2020","journal-title":"Drugs Context."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Aloke, C., Egwu, C.O., Aja, P.M., Obasi, N.A., Chukwu, J., Akumadu, B.O., Ogbu, P.N., and Achilonu, I. (2022). Current Advances in the Management of Diabetes Mellitus. Biomedicines, 10.","DOI":"10.3390\/biomedicines10102436"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: Mechanisms and advances in therapy","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11154-014-9289-5","article-title":"Effects of GLP-1 on appetite and weight","volume":"15","author":"Shah","year":"2014","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients with Type 2 Diabetes","volume":"146","author":"Marx","year":"2022","journal-title":"Circulation"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists","volume":"31","author":"Xie","year":"2025","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Latif, W., Lambrinos, K.J., Patel, P., and Rodriguez, R. (2025, September 30). Compare and Contrast the Glucagon-Like Peptide-1 Receptor Agonists (GLP1RAs), StatPearls, Available online: http:\/\/www.ncbi.nlm.nih.gov\/books\/NBK572151\/.","DOI":"10.31031\/NPMS.2025.01.000518"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","article-title":"Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022","volume":"64","author":"Watanabe","year":"2024","journal-title":"J. Am. Pharm. Assoc."},{"key":"ref_19","unstructured":"(2025, April 16). FAERS Public Dashboard\u2014FAQ, Available online: https:\/\/fis.fda.gov\/extensions\/FPD-FAQ\/FPD-FAQ.html#_Toc514144622."},{"key":"ref_20","first-page":"281","article-title":"Exenatide (Byetta) as a novel treatment option for type 2 diabetes mellitus","volume":"19","author":"Bond","year":"2006","journal-title":"Proc. (Bayl. Univ. Med. Cent.)"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"e70045","DOI":"10.1002\/edm2.70045","article-title":"Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies","volume":"8","author":"Wen","year":"2025","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_22","unstructured":"(2025, May 14). Zepbound (Tirzepatide) FDA Approval History. Drugs.com. Available online: https:\/\/www.drugs.com\/history\/zepbound.html."},{"key":"ref_23","unstructured":"(2026, March 20). Ozempic (semaglutide) FDA Approval History. Drugs.com. Available online: https:\/\/www.drugs.com\/history\/ozempic.html."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ivanescu, A., Popescu, S., Gaita, L., Albai, O., Braha, A., and Timar, R. (2024). Risk Factors for Cataracts in Patients with Diabetes Mellitus. J. Clin. Med., 13.","DOI":"10.3390\/jcm13237005"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ajo.2025.05.007","article-title":"Association of Glucagon-Like Peptide-1 Receptor Agonists with Optic Nerve and Retinal Adverse Events: A Population-Based Observational Study Across 180 Countries","volume":"277","author":"Lakhani","year":"2025","journal-title":"Am. J. Ophthalmol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1080\/14740338.2024.2419989","article-title":"Ocular adverse events associated with GLP-1 receptor agonists: A real-world study based on the FAERS database and network pharmacology","volume":"24","author":"Luo","year":"2025","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Massy, M., Marti, S., Hammer, H., and Hoepner, R. (2025). Increased vision impairment reports linked to semaglutide: Analysis of FDA adverse event data. BMC Med., 23.","DOI":"10.1186\/s12916-025-04031-z"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rentzeperi, E., Pegiou, S., Koufakis, T., Grammatiki, M., and Kotsa, K. (2022). Sex Differences in Response to Treatment with Glucagon-like Peptide 1 Receptor Agonists: Opportunities for a Tailored Approach to Diabetes and Obesity Care. J. Pers. Med., 12.","DOI":"10.3390\/jpm12030454"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e70063","DOI":"10.1111\/1753-0407.70063","article-title":"Sex Differences in the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists for Weight Reduction: A Systematic Review and Meta-Analysis","volume":"17","author":"Yang","year":"2025","journal-title":"J. Diabetes"},{"key":"ref_30","first-page":"158","article-title":"Effects of glycemic control on refraction in diabetic patients","volume":"3","author":"Li","year":"2010","journal-title":"Int. J. Ophthalmol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/bjo.77.3.145","article-title":"Transient hyperopia with lens swelling at initial therapy in diabetes","volume":"77","author":"Saito","year":"1993","journal-title":"Br. J. Ophthalmol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopha.2018.08.088","article-title":"Recent updates on GLP-1 agonists: Current advancements & challenges","volume":"108","author":"Sharma","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_33","first-page":"182","article-title":"Systemic Allergic Reaction to the GLP-1 Receptor Agonist Exenatide","volume":"30","author":"Steveling","year":"2014","journal-title":"J. Pharm. Technol. JPT Off. Publ. Assoc. Pharm. Tech."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jtos.2022.02.004","article-title":"Drug induced cicatrizing conjunctivitis: A case series with review of etiopathogenesis, diagnosis and management","volume":"24","author":"Singh","year":"2022","journal-title":"Ocul. Surf."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/aje\/kwac021","article-title":"Glucagon-Like Peptide 1 Receptor Agonists and Risk of Anaphylactic Reaction Among Patients with Type 2 Diabetes: A Multisite Population-Based Cohort Study","volume":"191","author":"Pradhan","year":"2022","journal-title":"Am. J. Epidemiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"13407","DOI":"10.1038\/s41598-025-92796-x","article-title":"Real-World pharmacovigilance analysis of drug-related conjunctivitis using the FDA adverse event reporting system database","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1111\/dom.13538","article-title":"Worsening of diabetic retinopathy with rapid improvement in systemic glucose control: A review","volume":"21","author":"Bain","year":"2019","journal-title":"Diabetes Obes. Metab."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging Causes of Drug\u2013Induced Anaphylaxis: A Review of Anaphylaxis\u2013Associated Reports in the FDA Adverse Event Reporting System (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/bmj.39323.586123.BE","article-title":"Pharmacovigilance in developing countries","volume":"335","author":"Pirmohamed","year":"2007","journal-title":"BMJ"},{"key":"ref_40","unstructured":"FDA (2025, May 13). About FDA, Available online: https:\/\/www.fda.gov\/about-fda."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.2147\/TCRM.S137144","article-title":"Relevance of the Weber effect in contemporary pharmacovigilance of oncology drugs","volume":"13","author":"Arora","year":"2017","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e34837","DOI":"10.1016\/j.heliyon.2024.e34837","article-title":"Pharmacovigilance analysis of orlistat adverse events based on the FDA adverse event reporting system (FAERS) database","volume":"10","author":"Zhu","year":"2024","journal-title":"Heliyon"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/6\/2464\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,23]],"date-time":"2026-03-23T16:04:45Z","timestamp":1774281885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/15\/6\/2464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":42,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3]]}},"alternative-id":["jcm15062464"],"URL":"https:\/\/doi.org\/10.3390\/jcm15062464","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,23]]}}}